
-
Gossamer Bio NasdaqGS:GOSS Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Location: 3115 Merryfield Row, San Diego, CA, 92121, United States | Website: https://www.gossamerbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
146.9M
Cash
294.5M
Avg Qtr Burn
-867K
Short % of Float
5.48%
Insider Ownership
3.51%
Institutional Own.
75.48%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Seralutinib (GB002) (Inhaled PDGF receptor kinase inhibitor) Details Rare diseases, Pulmonary arterial hypertension, Lung disease | Phase 3 Data readout | |
Seralutinib (GB002) Details Lung disease, Pulmonary hypertension associated with interstitial lung disease | Phase 3 Initiation | |
Failed Discontinued | ||
GB1275 (Oral CD11b modulator) Details Solid tumor/s, Esophageal cancer, Cancer, Gastric cancer | Failed Discontinued | |
GB004 (Oral HIF-1α stabilizer) Details Ulcerative colitis | Failed Discontinued |